Results: Rituximab was prescribed off‐label to 66 patients for 24 autoimmune diseases. The majority of patients (62.1%) were Aboriginal and 60.6% female.
eBook Title: Off‐label Use of Rituximab in Autoimmune Disease in the Top End of the Northern Territory, 2008–2016
Author:
Published on 2018 by
Abstract: Background: Rituximab, an anti‐CD20 B‐cell depleting monoclonal antibody, is increasingly prescribed off‐label for a range of autoimmune diseases. There has not previously been an audit of off‐label rituximab use in the Northern Territory, where the majority of patients are Aboriginal. Aims: To evaluate retrospectively off‐label rituximab use in autoimmune diseases in the Top End of the Northern Territory. Methods: We performed a retrospective audit of 8 years of off‐label rituximab use at the Royal Darwin Hospital, the sole tertiary referral centre for the Darwin, Katherine and East Arnhem regions. Electronic and paper records were reviewed for demographic information, diagnosis/indication for rituximab, doses, previous/concomitant immunosuppression, clinical outcomes and specific adverse events. Results: Rituximab was prescribed off‐label to 66 patients for 24 autoimmune diseases. The majority of patients (62.1%) were Aboriginal and 60.6% female. The most common indications were refractory/relapsing disease despite standard therapies (68.7%) or severe disease with rituximab incorporated into an induction immunosuppressive regimen (19.4%). Systemic lupus erythematosus was the underlying diagnosis in 28.8% of cases. A clinically significant response was demonstrated in 74.2% of cases overall. There were 18 clinically significant infections; however, 13 were in patients receiving concurrent immunosuppressive therapy. There was a total of nine deaths from any cause. Conclusion: Rituximab has been used off‐label for a range of autoimmune diseases in this population with a high proportion of Aboriginal patients successfully and safely in the majority of cases.
From the most popular Autoimmune Disease Books, Off‐label Use of Rituximab in Autoimmune Disease in the Top End of the Northern Territory, 2008–2016 is the one of great book to have. You can download ebook from:
entitled: Off‐label Use of Rituximab in Autoimmune Disease in the Top End of the Northern Territory, 2008–2016 here. There are so many ebooks about Off‐label Use of Rituximab in Autoimmune Disease in the Top End of the Northern Territory, 2008–2016 that are available to download. Thinking of having free ebooks by Download Off‐label Use of Rituximab in Autoimmune Disease in the Top End of the Northern Territory, 2008–2016 ebook rather than buy? You are in the right place. Download ebook Off‐label Use of Rituximab in Autoimmune Disease in the Top End of the Northern Territory, 2008–2016 by: .
- Book was ranked at 34 by Google Books for Off‐label Use of Rituximab in Autoimmune Disease in the Top End of the Northern Territory, 2008–2016
- Off‐label Use of Rituximab in Autoimmune Disease in the Top End of the Northern Territory, 2008–2016 published by since 2018 with ISBNs. The book ISBN 13 Code is and ISBN 10 Code is
- Reading Mode in Text Status is false and Reading Mode in Image Status is false
- The book has " Pages" is Printed at BOOK under Category
- Rated by Raters and have average rate at ""
- eBook Maturity (Adult Book) status is NOT_MATURE
- eBook written in en
- Book Preview Address: http://books.google.com/books?id=z0dntgEACAAJ&dq=Autoimmune+Disease&hl=&cd=273&source=gbs_api
Book Preview
- Server 1: FAST DOWNLOAD
- Server 2: SECURE DOWNLOAD
- Server 3: FAST DOWNLOAD